Allogene Therapeutics (ALLO) Change in Account Payables (2018 - 2026)
Allogene Therapeutics (ALLO) reported Change in Account Payables of $663000.0 for Q1 2026, up 297.32% on a YoY basis from $166867.4 in Q1 2025, and up 10.68% sequentially from $599000.0 in Q4 2025.
Allogene Therapeutics (ALLO) Change in Account Payables (2018 - 2026) Analysis & Trends
Allogene Therapeutics (ALLO) has 9 years of Change in Account Payables data on file, last reported at $663000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 297.32% year-over-year to $663000.0; the trailing twelve-month figure through Mar 2026 stood at -$232000.0 (up 67.82% YoY), and the FY2025 full-year result was -$1.2 million, down 144.73% from the prior year.
- Change in Account Payables advanced to $663000.0 in Q1 2026, from $599000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.8 million in Q2 2024 to a low of -$7.2 million in Q3 2024.
- A 5-year average of -$217941.2 and a median of -$118000.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables slumped 491.61% in 2023 and soared 1661.76% in 2025, its largest moves.
- Tracing ALLO's Change in Account Payables over 5 years: stood at $2.9 million in 2022, then tumbled by 110.28% to -$302000.0 in 2023, then surged by 111.26% to $34000.0 in 2024, then soared by 1661.76% to $599000.0 in 2025, then increased by 10.68% to $663000.0 in 2026.
- Business Quant data shows ALLO's Change in Account Payables at $663000.0 in Q1 2026, $599000.0 in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | 663,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 663,000.00 |
| Mar 31, 2026 | 663,000.00 |
| Dec 31, 2025 | 599,000.00 |
| Dec 31, 2025 | 599,000.00 |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -422,000.00 |
| Jun 30, 2025 | -422,000.00 |
| Mar 31, 2025 | -336,000.00 |
| Mar 31, 2025 | -336,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Dec 31, 2024 | 34,000.00 |
| Sep 30, 2024 | -7.23 Mn |
| Sep 30, 2024 | -7.23 Mn |
| Jun 30, 2024 | 6.81 Mn |
| Jun 30, 2024 | 6.81 Mn |
| Mar 31, 2024 | -118,000.00 |
| Mar 31, 2024 | -118,000.00 |
| Dec 31, 2023 | -302,000.00 |
| Dec 31, 2023 | -302,000.00 |